
    
      The pharmacokinetic characteristics of golimumab will be assessed by using blood and stool
      samples; collected during induction and maintenance treatment Patients will undergo 13-16
      blood sample collections, 13-16 stool sample collections and 3 endoscopies during 16 hospital
      visits in 1 year. They are also asked to fill in a short questionnaire (9x). At endoscopy
      visits a questionnaire regarding quality of life will be taken.The population
      pharmacokinetics of golimumab will be assessed using nonlinear mixed-effects modelling
      (NON-MEM).
    
  